Abstract
Objective: To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax ™ ) given as a third (booster) dose to individuals primed with different primary vaccine regimens. Methods: Individuals primed with two doses of COVID-19 vaccines for at least 3 months were enrolled and assigned to five groups according to their primary vaccine regimens: CoronaVac, BBIBP-CorV, AZD1222, BNT162b2, and CoronaVac/AZD1222. Immunogenicity analysis was performed to determine binding antibodies, neutralizing activity, and the T-cell response. Results: Overall, 215 individuals were enrolled and boosted with the Covovax ™ vaccine. The reactogenicity achieved was mild-to-moderate. Most participants elicited a high level of binding and neutralizing antibody responses against wild type and omicron variants following the booster dose. The 197 participants were classified by anti-N IgG. Of these, 141/197 (71.6%) were a seronegative population, and neutralizing activity and IFN-γ release were further monitored. A booster dose could elicit neutralizing activity to wild type and omicron variants by more than 95% and 70% inhibition at 28 days, respectively. The Covovax ™ vaccine could elicit a cell-mediated immune response. Conclusion: The protein subunit vaccine (Covovax ™ ) can be proposed as a booster dose after two different priming dose regimens. It has strong immunogenicity and good safety profiles.

This publication has 22 references indexed in Scilit: